Results 111 to 120 of about 40,773 (330)

PCSK9 genetic variants and cognitive abilities:a large-scale Mendelian randomization study [PDF]

, 2021
Introduction: PCSK9 inhibitors lower low-density lipoprotein (LDL) cholesterol and are efficacious at reducing vascular disease, however questions remain about potential effects on cognitive function.
Banach, Maciej, Davey Smith, George, Gill, Jason M. R., Holmes, Michael V, Lyall, Donald M., Pell, Jill P, Sattar, Naveed, Ward, Joey   +7 more
core   +2 more sources

Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms

Circulation Research, 2022
Background: Activated macrophages contribute to the pathogenesis of vascular disease. Vein graft failure is a major clinical problem with limited therapeutic options. PCSK9 (proprotein convertase subtilisin/kexin 9) increases low-density lipoprotein (LDL)
Shunsuke Katsuki, Prabhash Kumar Jha, A. Lupieri, T. Nakano, Livia S A Passos, M. Rogers, Dakota R. Becker-Greene, Thanh-Dat Le, J. Decano, Lang Ho Lee, G. C. Guimarães, Ilyes Abdelhamid, A. Halu, A. Muscoloni, Carlo Vittorio Cannistraci, Hideyuki Higashi, Hengmin Zhang, Amélie Vromman, P. Libby, C. Keith Ozaki, Amitabh Sharma, Sasha A. Singh, E. Aikawa, M. Aikawa   +23 more
semanticscholar   +1 more source

Mapping Hsp104 interactions using cross‐linking mass spectrometry

FEBS Open Bio, EarlyView.
This study examines how cross‐linking mass spectrometry can be utilized to analyze ATP‐induced conformational changes in Hsp104 and its interactions with substrates. We developed an analytical pipeline to distinguish between intra‐ and inter‐subunit contacts within the hexameric homo‐oligomer and discovered contacts between Hsp104 and a selected ...
Kinga Westphal, Karolina Michalska, Andrzej Joachimiak, Lukasz A. Joachimiak   +3 more
wiley   +1 more source

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor [PDF]

, 2009
PCSK9 (proprotein convertase subtilisin/kexin type 9) promotes degradation of the LDLR [LDL (low-density lipoprotein) receptor] through an as-yet-undefined mechanism, leading to a reduction in cellular LDLc (LDL-cholesterol) and a concomitant increase in
Abifadel, Benjannet, Benjannet, Berge, Bottomley, Cameron, Christopher J. Duff, Condreay, Cunningham, Dubuc, Fisher, Frank-Kamenetsky, Graham, Horton, Ian T. Kirby, Kwon, Lagace, Li, Lopez, Martin J. Scott, Maxwell, McNutt, Nassoury, Nigel M. Hooper, Park, Piper, Pollex, Rader, Rashid, Scott, Shan, Steve L. Martin, Sue E. Hutchinson, Zhang   +33 more
core   +4 more sources

PCSK9 Inhibitors

Journal of the American College of Cardiology, 2017
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors substantially reduce low-density lipoprotein cholesterol, but it is presently unclear whether they also reduce mortality. The list prices of PCSK9 inhibitors in the United States (>$14,500 per year) are >100× higher than generic statins, and only a small fraction of their higher cost is ...
Mark A. Hlatky, Dhruv S. Kazi
openaire   +3 more sources

PCSK9 Promotes the Malignancy of Triple‐negative Breast Cancer Cells by Reducing Cholesterol Levels at the Plasma Membrane to Activate EGFR and HER3

Advanced Science, EarlyView.
By decreasing cholesterol and lipid raft levels in the plasma membrane, proprotein convertase subtilisin/kexin type 9 (PCSK9) boosts human epidermal growth factor receptor 1 and 3 (EGFR and HER3) activation, driving tumor growth and metastasis in triple‐negative breast cancer (TNBC).
Tianhong Li, Renfei Wu, Kathy Qian Luo
wiley   +1 more source

Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study

Frontiers in Genetics, 2021
Pharmacological inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) is an established therapeutic option to treat hypercholesterolemia, and plasma PCSK9 levels have been implicated in cardiovascular disease incidence.
Isabela Bensenor, Kallyandra Padilha, Isabella Ramos Lima, Raul Dias Santos, Gilles Lambert, Stéphane Ramin-Mangata, Marcio S Bittencourt, Alessandra C Goulart, Itamar S. Santos, Jose G Mill, Jose E Krieger, Paulo A. Lotufo, Alexandre C. Pereira   +12 more
doaj   +1 more source

Macrophage HM13/SPP Enhances Foamy Macrophage Formation and Atherogenesis

Advanced Science, EarlyView.
Previous research suggests that AIP may prevent atherogenic foamy macrophage formation. This study reveals that AIP, via its chaperone interaction with AHR, inhibits p38‐c‐JUN‐mediated transactivation of HM13, which encodes the ERAD protease HM13/SPP. HM13/SPP promotes foamy macrophage formation in addition to atherogenesis and plaque foamy macrophage ...
Yu Cao, Qirong Xie, Qiang Zheng, Jingping Zhang, Mengyu Yao, Zhongyong Du, Lujun Zhang, Tianyang Hu, Yunli Zhao, Jianlin Du, Yongyong Li, Yuxing Feng, ND Melgiri, Xiaodong Zhao, Rongzhong Huang, Yang Sun   +15 more
wiley   +1 more source

Familial hypercholesterolemia: a systematic review of guidelines on genetic testing and patient management [PDF]

, 2017
BACKGROUND: Familial hypercholesterolemia (FH) is an autosomal-dominant hereditary disorder of lipid metabolism that causes lifelong exposure to increased LDL levels resulting in premature coronary heart disease and, if untreated, death.
Baccolini, Valentina, D'Andrea, Elvira, De Vito, Corrado, Massimi, Azzurra, Migliara, Giuseppe, Rosso, Annalisa, Villari, Paolo   +6 more
core   +2 more sources

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. [PDF]

, 2021
Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is secreted mostly by hepatocytes and to a lesser extent by the intestine, pancreas, kidney, adipose tissue, and vascular cells.
Döring, Yvonne, Sundararaman, Sai Sahana, van der Vorst, Emiel P C   +2 more
core   +1 more source